甲状腺癌组织中尿激酶型纤溶酶原激活物和抑制物的表达及其临床意义  

The clinical significance of the expression of urokinase type plasminogen activator and plasminogen activator inhabitor in thyroid carcinomas

作　　者：曲牟文[1] 刘建东[1] 杨景国[1] 魏文杰[1] 魏玲[2] 

机构地区：[1]北京市普仁医院普外科,北京100062 [2]山东省肿瘤防治研究院基础研究中心

出　　处：《临床肿瘤学杂志》2004年第1期44-47,共4页Chinese Clinical Oncology

摘　　要：目的 :研究纤溶酶原激活物 (uPA)和抑制物 (PAI 1)在甲状腺癌组织中的不同表达 ,总结其在甲状腺癌的发生、发展及侵袭转移过程中的规律和对临床的指导意义。方法 :采用酶联免疫吸附 (ELISA)法检测 4 2例甲状腺癌和 30例良性甲状腺肿瘤组织及正常甲状腺组织中uPA和PAI 1含量 ,从良恶性、临床分期、病理类型等不同方面分别进行对照分析 ,比较其有无差异。结果 :甲状腺瘤组织的uPA含量高于正常甲状腺组织 (P <0 0 5 ) ,PAI 1含量和正常甲状腺组织比较无显著性差异 (P >0 0 5 )。甲状腺癌组织中uPA和PAI 1含量明显高于良性甲状腺肿瘤和癌旁组织 (P <0 0 1) ,且和临床分期呈正相关 (r分别为 0 72 3和 0 795 ,P <0 0 5 )。周围淋巴结转移组的uPA和PAI 1含量明显高于无转移组 (P <0 0 5 )。未分化癌的uPA和PAI 1含量高于乳头状癌和滤泡状癌 (P <0 0 5 ) ,乳头状癌和滤泡状癌uPA值和PAI 1含量比较无显著性差异 (P >0 0 5 ) ,髓样癌的uPA值和PAI 1的含量最低。结论 :检测组织中uPA和PAI 1含量可能对甲状腺癌的侵犯范围。Objective:To investigate the expression of urokinase type plasminogen activator(uPA) and plasminogen activator inhibitor(PAI-1) in the tissue of thyroid carcinomas,sum up the role of these factors in the occurrence,progression,invasion in thyroid carcinomas and their significances for clinical practice.Methods:The levels of uPA and PAI-1 in tissue was determined by ELISA method in 42 cases of thyroid carcinomas,30 cases of benign thyroid tumor and normal thyroid tissues.The levels of these two factors were compared between benign and malignant diseases,various clinical stages and different pathologic types.Results:The level of uPA in thyroid carcinomas tissue was significantly higher than that of normal group(P<0 05),but the level of PAI-1 was not different between two groups.The level of uPA and PAI-1 in tissue of thyroid carcinomas were significantly higher than that in benign tumour tissue and in tissues beside carcinomas(P<0 01),and were positively correlated to clinical stages of thyroid tumor,Compared with the group of no lymph node metastasis,the uPA level in lymph node metastasis group was higher(P<0 05).The level of uPA and PAI-1 in anaplastic thyroid cancer was higher than that in papillary thyroid cancer and follicular thyroid cancer(P<0 05).There was no different levels of these two factors between papillary thyroid cancer and follicular thyroid cancer.In comparison with other kind of cancers,the level of uPA and PAI-1 in medullary thyroid cancer was lowest.Conclusion:Measuring levels of uPA and PAI-1 in tissues may help to evaluate the extent of cancer invasion,lymph node metastasis and prognosis of thyroid cancer.

关 键 词：甲状腺癌 尿激酶型纤溶酶原激活物 UPA PAI-1 抑制物 肿瘤 

分 类 号：R736.1[医药卫生—肿瘤]